Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -32,11k | 1,60M | Verkauf | 49,81 | 357,64k | -8,24% |
| 2026-05-15 | Mr. Christopher J. SennerExec. VP & CFO | -40,89k | 2,09M | Sale to Issuer | 51,10 | 551,13k | -6,91% |
| 2026-05-18 | Dr. Brenda J. HeftiSenior VP & General Counsel | -6,63k | 332,64k | Automatic Disposition | 50,21 | 6,25k | -51,46% |
| 2026-05-18 | Mr. Christopher J. SennerExec. VP & CFO | -34,90k | 1,75M | Verkauf | 50,00 | 551,13k | -5,96% |
| 2026-05-15 | Dr. Brenda J. HeftiSenior VP & General Counsel | -6,41k | 327,60k | Sale to Issuer | 51,10 | 6,25k | -50,64% |
| 2026-05-18 | Dr. Michael M. MorrisseyCEO, President & Director | -124,05k | 0,00 | Other Disposition | - | 3,38M | -3,54% |
| 2026-05-15 | Dr. Michael M. MorrisseyCEO, President & Director | -128,50k | 6,57M | Sale to Issuer | 51,10 | 3,38M | -3,66% |
| 2026-05-15 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -33,27k | 1,70M | Sale to Issuer | 51,10 | 389,75k | -7,86% |
| 2026-05-15 | Dr. Dana T. AftabExec. VP of Research & Development | -30,58k | 1,56M | Sale to Issuer | 51,10 | 238,06k | -11,38% |
| 2026-05-07 | Dr. Maria C. FreireIndependent Director | -20,63k | 541,23k | Derivative Exercise and Sale | 19,77 - 46,00 | 91,01k | - |
| 2026-05-07 | Dr. Mary C. BeckerleIndependent Director | -3,86k | 186,82k | Verkauf | 48,45 | 17,52k | -18,04% |
| 2026-05-07 | Dr. Mary C. BeckerleIndependent Director | -3,86k | 97,21k | Derivative Exercise and Sale | 23,24 - 48,45 | 17,52k | - |
| 2026-02-24 | Dr. Michael M. MorrisseyCEO, President & Director | -100,28k | 0,00 | Other Disposition | - | 2,01M | -4,76% |
| 2026-02-24 | Dr. Dana T. AftabExec. VP of Research & Development | -47,92k | 2,13M | Verkauf | 44,50 | 207,90k | -18,73% |
| 2026-02-19 | Dr. Dana T. AftabExec. VP of Research & Development | -29,87k | 1,32M | Verkauf | 44,35 | 255,82k | -10,46% |
| 2026-02-18 | Mr. Jack L. WyszomierskiIndependent Director | -20,63k | 500,17k | Derivative Exercise and Sale | 19,77 - 44,01 | 270,13k | - |
| 2026-02-18 | Mr. Jack L. WyszomierskiIndependent Director | -78,94k | 3,47M | Automatic Disposition | 44,01 | 270,13k | -22,61% |
| 2026-02-17 | Ms. Julie Anne SmithIndependent Director | -106,54k | 2,63M | Derivative Exercise and Sale | 18,19 - 44,50 | 10,78k | - |
| 2026-02-13 | Dr. Sue Gail EckhardtIndependent Director | -3,86k | 168,85k | Automatic Disposition | 43,79 | 0,00 | -100,00% |
| 2026-02-18 | Dr. Brenda J. HeftiSenior VP & General Counsel | -18,67k | 821,62k | Automatic Disposition | 44,01 | 6,08k | -75,42% |
| 2026-02-15 | Dr. Brenda J. HeftiSenior VP & General Counsel | -5,43k | 238,49k | Sale to Issuer | 43,92 | 6,08k | -47,16% |
| 2026-02-15 | Dr. Dana T. AftabExec. VP of Research & Development | -39,21k | 1,72M | Sale to Issuer | 43,92 | 285,69k | -12,07% |
| 2026-02-13 | Mr. Robert Lee OliverIndependent Director | -9,09k | 221,11k | Derivative Exercise and Sale | 19,28 - 43,61 | 2,22k | - |
| 2026-02-13 | Mr. Robert Lee OliverIndependent Director | -21,16k | 929,01k | Verkauf | 43,90 | 2,22k | -90,51% |
| 2026-02-13 | Dr. Michael M. MorrisseyCEO, President & Director | -494,70k | 10,98M | Derivative Exercise and Sale | 21,31 - 43,92 | 2,11M | - |
| 2026-02-17 | Dr. Michael M. MorrisseyCEO, President & Director | -371,13k | 0,00 | Other Disposition | - | 2,11M | -14,97% |
| 2026-02-13 | Mr. Christopher J. SennerExec. VP & CFO | -64,90k | 2,81M | Verkauf | 43,00 - 43,67 | 551,13k | -10,53% |
| 2026-02-15 | Mr. Christopher J. SennerExec. VP & CFO | -35,87k | 1,58M | Sale to Issuer | 43,92 | 551,13k | -6,11% |
| 2026-02-17 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -67,81k | 2,95M | Verkauf | 43,50 - 43,84 | 0,00 | -100,00% |
| 2026-02-15 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -31,48k | 1,38M | Sale to Issuer | 43,92 | 0,00 | -100,00% |
| 2026-01-15 | Mr. Christopher J. SennerExec. VP & CFO | -40,46k | 1,83M | Sale to Issuer | 45,23 | 585,40k | -6,46% |
| 2026-01-15 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -32,33k | 1,46M | Sale to Issuer | 45,23 | 37,42k | -46,35% |
| 2026-01-15 | Dr. Dana T. AftabExec. VP of Research & Development | -27,25k | 1,23M | Sale to Issuer | 45,23 | 247,84k | -9,91% |
| 2026-01-15 | Dr. Michael M. MorrisseyCEO, President & Director | -139,52k | 6,31M | Sale to Issuer | 45,23 | 1,87M | -6,95% |
| 2025-11-10 | Farallon Capital Management, L.L.C.Unternehmen | 96,37k | 3,95M | Kauf | 40,32 - 40,96 | 15,71M | 0,62% |
| 2025-11-13 | Farallon Capital Management, L.L.C.Unternehmen | -4,17M | 0,00 | Verkauf | 40,77 - 44,50 | 15,71M | -20,97% |
| 2025-11-25 | Caligan Partners, LPUnternehmen | 27,53k | 1,19M | Kauf | 43,12 | 1,55M | 1,80% |
| 2025-11-20 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -72,23k | 3,05M | Verkauf | 41,77 - 42,58 | 0,00 | -100,00% |
| 2025-11-21 | Dr. Dana T. AftabExec. VP of Research & Development | -24,00k | 0,00 | Other Disposition | - | 215,31k | -10,03% |
| 2025-11-17 | Mr. Robert Lee OliverIndependent Director | -1,04k | 0,00 | Other Disposition | - | 23,38k | -4,27% |
| 2025-11-11 | Dr. Mary C. BeckerleIndependent Director | -5,78k | 108,68k | Derivative Exercise and Sale | 23,24 - 42,03 | 0,00 | - |
| 2025-11-11 | Dr. Mary C. BeckerleIndependent Director | -18,84k | 789,31k | Verkauf | 41,90 | 0,00 | -100,00% |
| 2025-11-11 | Dr. Michael M. MorrisseyCEO, President & Director | -341,55k | 0,00 | Other Disposition | - | 1,73M | -16,47% |
| 2025-11-11 | Dr. Dana T. AftabExec. VP of Research & Development | -48,38k | 2,06M | Verkauf | 42,50 | 239,31k | -16,82% |
| 2025-11-12 | Dr. Stelios PapadopoulosCo-Founder & Independent Chair of the Board | -100,00k | 4,36M | Verkauf | 43,55 | 1,18M | -7,82% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
